Avenue Therapeutics Files 8-K on Security Holder Vote

TL;DR

AVTX shareholders voted on something important March 6th. Details TBD.

AI Summary

Avenue Therapeutics, Inc. filed an 8-K on March 8, 2024, reporting that a matter was submitted to a vote of its security holders on March 6, 2024. The filing does not disclose the specific details of the vote or the outcome.

Why It Matters

This filing indicates a significant event where shareholders voted on a matter, which could impact the company's future direction or governance.

Risk Assessment

Risk Level: medium — The filing is a procedural update about a shareholder vote, but the lack of detail on the vote's subject and outcome introduces uncertainty.

Key Players & Entities

• Avenue Therapeutics, Inc. (company) — Registrant
• March 6, 2024 (date) — Date of earliest event reported
• March 8, 2024 (date) — Date of report

FAQ

Filing Documents

• tm248309d1_8k.htm (8-K) — 22KB
• 0001104659-24-032401.txt ( ) — 190KB
• atxi-20240306.xsd (EX-101.SCH) — 3KB
• atxi-20240306_lab.xml (EX-101.LAB) — 33KB
• atxi-20240306_pre.xml (EX-101.PRE) — 22KB
• tm248309d1_8k_htm.xml (XML) — 4KB

07Submission of Matters to Vote of Security Holders

Item 5.07Submission of Matters to Vote of Security Holders. Effective March 6, 2024, the holders of a majority of the voting power of the capital stock of Avenue Therapeutics, Inc. (the " Company ") executed a written consent approving a grant of discretionary authority to the board of directors of the Company (the " Board ") to, without further stockholder approval, effect a reverse stock split of the Company's issued and outstanding common stock within a range of between 30-for-1 and 75-for-1 (with the Board being authorized to determinate the exact ratio) (the " Reverse Stock Split ") by filing an amendment (the " Amendment ") to the Company's Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. The written consent was signed by the holders of 3,133,886 shares of the Company's common stock and 250,000 shares of the Company's Class A Preferred Stock. Each share of common stock entitles the holder thereof to one vote on all matters submitted to stockholders and each share of Class A Preferred Stock has the voting power of 1.1 times (A) the number of outstanding shares of common stock plus (B) the whole shares of Company common stock into which the outstanding shares of Class A Preferred Stock are convertible, divided by the number of outstanding shares of Class A Preferred Stock, or 194.8 votes per share as of March 6, 2024. Accordingly, the holders of approximately 56% of the voting power of the Company's capital stock as of March 6, 2024 signed the written consent approving the Reverse Stock Split and the Amendment. The Board also approved the Reverse Stock Split and the Amendment. Pursuant to rules adopted by the Securities and Exchange Commission under the Securities Exchange Act of 1934, a Schedule 14C information statement will be filed with the Securities and Exchange Commission and sent or provided to the stockholders of the Company.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVENUE THERAPEUTICS, INC. (Registrant) Date: March 8, 2024 By: /s/ David Jin David Jin Interim Principal Financial Officer and Chief Operating Officer

View Full Filing

View this 8-K filing on SEC EDGAR